Triglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials - Top-Institutions - MDSpire

Triglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials

  • By

  • Jessica Schubert

  • Emil Hagström

  • Johan Westerbergh

  • Margrét Leosdottir

  • Kausik Ray

  • February 19, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Lipidology
    • Cardiovascular Research

  • #2

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Preventive Medicine
    • Epidemiology

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Lipidology
    • Clinical Research

  • #4

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Sweden

    Key Differentiators

    • Cardiology
    • Epidemiology
    • Clinical Trials

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Cardiology
    • Lipidology
    • Clinical Research

Original Source(s)

Triglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials

  • by Jessica Schubert, Emil Hagström, Johan Westerbergh, Margrét Leosdottir, Kausik Ray

  • February 19, 2026

Related Content

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.

Characteristics of patients with cryptogenic stroke and atrial fibrillation detected using insertable cardiac monitoring in the chronic phase: a subanalysis of the LOOK study